User Preferences for Two Types of LLIN in Endemic Areas of Visceral Leishmaniasis

*<p>Differences are significant at <i>p</i><0.05.</p>a<p>Due to multiple responses, the percentages exceed 100.</p>b<p>Reports of itching and sneezing increased after the first interview.</p

PCR primers for ISC-SLG.

<p>PCR primers for ISC-SLG.</p

Analytical sensitivity of seven PCRs (Table 2), analyzed on agarose gel.

<p>Only the relevant part of the gels is shown. <i>L</i>. <i>donovani</i> strain MHOM/NP/2003/BPK282/0cl4 DNA was used. The DNA amount used per reaction ranging from 20 ng to 0.2 pg, is indicated on top. The ISC-SLG PCRs are indicated on the left.</p

Year-wise distribution of genotypes.

<p>Years of parasite isolation are at the bottom, genotypes were identified by WGS or ISC-SLG, as indicated. No samples were available from 2005 to 2008, indicated by a double vertical line. Genotypes are shown on the left. The diameter of bubble plots represents the number found in each year. When isolates were derived from different disease episodes of the same patient, they are shown only if the genotypes in these episodes were different, thereby excluding 5/98 and 2/106 isolates characterized by WGS and ISC-SLG respectively.</p

Genotype distribution in relation to treatment outcome for all episodes for which treatment was completed.

<p>Outcomes of three drugs (SSG, MIL, AmB) are given at the bottom, genotypes are shown on the left. Cure: treatment completed, absence of clinical sign and symptoms of VL until six months for SSG and AmB, and one year for MIL; Death: death of patient during course of treatment; Non-response: persisting clinical signs and symptoms of VL, and positive bone marrow smear after treatment; Relapse: reappearance of disease symptoms and/or positive bone marrow smear after initial cure and during a 12 month follow-up. # denotes two MIL treated patients who relapsed but presented infection with a different genotype before and after relapse: , BPK519; # BPK676, see <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005420#pntd.0005420.s001" target="_blank">S1 Database</a> for details. The diameter of bubble plots is proportional to the number of the genotypes for each treatment outcome.</p

Spatial-temporal distribution of each <i>L</i>. <i>donovani</i> genotype.

<p>The sampling districts (South-East Nepal) are shown at the bottom right panel. BPKIHS (Dharan) is indicated with a red cross. One ISC001 isolate of 2014 originated from the Banke district, which is not shown because it is located in western Nepal. Data can be viewed interactively from <a href="https://microreact.org/project/SNP_Genotypes_Nepal" target="_blank">https://microreact.org/project/SNP_Genotypes_Nepal</a></p

Country-specific enrolment characteristics of patients and controls in the NIDIAG study on persistent digestive disorders.

<p>Country-specific enrolment characteristics of patients and controls in the NIDIAG study on persistent digestive disorders.</p

Diagnostic challenges encountered during the NIDIAG study on persistent digestive disorders and proposed solutions.

<p>Diagnostic challenges encountered during the NIDIAG study on persistent digestive disorders and proposed solutions.</p

Laboratory diagnostic techniques used and internally compared in the NIDIAG study on persistent digestive disorders.

<p>Laboratory diagnostic techniques used and internally compared in the NIDIAG study on persistent digestive disorders.</p

Principal elements of the NIDIAG digestive study and the respective standard operating procedures (SOPs) used.

<p>Principal elements of the NIDIAG digestive study and the respective standard operating procedures (SOPs) used.</p